Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is converted inside cells to the active metabolite SN‑38. SN‑38 inhibits the enzyme topoisomerase I, which is essential for DNA replication. By preventing DNA strand religation, the drug causes DNA damage that leads to cancer cell death.

The prescribed dose of Irinotecan Accord is determined by the treating oncologist based on factors such as the patient’s body surface area, overall health, liver function, and prior chemotherapy exposure. No fixed dosing schedule is provided here; the prescriber tailors the regimen to each individual.

Safety data for Irinotecan in pregnancy and lactation are limited. Because the drug can cross the placenta and may be excreted in breast milk, it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as topotecan (another topoisomerase I inhibitor) and from antimetabolites like 5‑fluorouracil. Compared with some alternatives, Irinotecan often shows activity in tumors resistant to 5‑FU, but it carries a distinct toxicity profile, notably higher rates of diarrhea and neutropenia.

Irinotecan Accord should be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain throughout the journey.

Irinotecan Accord is given by intravenous infusion, typically over 30 to 90 minutes depending on the regimen. The infusion is performed in a clinical setting under the supervision of qualified healthcare professionals, who monitor the patient for immediate reactions and adjust the infusion rate as needed.

The most serious risks include severe neutropenia that can lead to infection, febrile neutropenia, and life‑threatening diarrhea (colitis). Additionally, rare but severe allergic reactions such as anaphylaxis may occur. Patients should be closely monitored for signs of infection, fever, or persistent gastrointestinal symptoms.

Irinotecan should be avoided in patients with known hypersensitivity to the drug or its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant liver dysfunction that cannot be managed. Caution is also advised for individuals with known UGT1A1*28 polymorphism due to increased toxicity risk.